Topical Timolol for Periocular Hemangioma: Report of Further Study

Topical timolol maleate for treatment of infantile haemangiomas: preliminary results of a prospective study

“…Studies on the pharmacokinetics and beta‐blocking effects of transdermal timolol patches (5% timolol, 0.2 mg/cm 2 ) found plasma concentration levels to be below the detection limit after application for 48 h 7 . Consistent with the latter, in our study and in the other reported cases, timolol has to date not produced any systemic adverse reactions when used to treat IHs in the available formulations of 0.1% and 0.5% 2–4 . Nevertheless, the available safety data are still insufficient, and dermatologists should be alert for the known side‐effects of beta‐blockers and thus monitor infants accordingly.…”

Topical timolol maleate for treatment of infantile haemangiomas: preliminary results of a prospective study

“…Studies on the pharmacokinetics and beta‐blocking effects of transdermal timolol patches (5% timolol, 0.2 mg/cm 2 ) found plasma concentration levels to be below the detection limit after application for 48 h 7 . Consistent with the latter, in our study and in the other reported cases, timolol has to date not produced any systemic adverse reactions when used to treat IHs in the available formulations of 0.1% and 0.5% 2–4 . Nevertheless, the available safety data are still insufficient, and dermatologists should be alert for the known side‐effects of beta‐blockers and thus monitor infants accordingly.…”

Oral Propranolol in the Management of Periocular Capillary Hemangiomas

“…31 Overall, however, the drug seems to be very safe with no serious adverse effects reported when used for this condition. 32 The authors also reported reduction in the average astigmatism from 2.5 to 1.0 D in their patients. Ni and colleagues treated 7 patients with superficial periocular hemangiomas; none of the patients underwent any previous treatment and all were treated using 0.5% solution of timolol maleate.…”

“…' The Role of Topical b Blockers Topical b blockers have been suggested as a safe and effective treatment for superficial hemangiomas with reduced systemic side effects. 32 This experience has been duplicated in other reports that have showed regression or arrested growth in lesions using timolol gel. The solution was spread over the lesion 2 times a day and the authors found a reduction in the hemangiomas by 55% to 95% over a period of 1 to 6 months.…”

Treatment of superficial infantile hemangiomas with timolol: Evaluation of short-term efficacy and safety in infants

“…As expected, no systemic adverse reactions were observed during the treatment period of the study. Furthermore, no adverse effects have been reported in previous studies (2,7,8), with the exception of mild pruritus over the lesion following four weeks of treatment in a case where timolol application was used to treat an 18-month-old female with ulcerated hemangiomas associated with PHACE syndrome (5). In the experience of the authors, patients with bronchial asthma have not experienced attacks during treatment, and it is therefore proposed that timolol may be safely considered for use in the treatment of IH with bronchial asthma, sinus bradycardia and second- and third-degree atrioventricular block; however, there is a requirement for these patients to be observed closely during treatment.…”

Topical timolol maleate for treatment of infantile haemangiomas: preliminary results of a prospective study

“…Studies on the pharmacokinetics and beta‐blocking effects of transdermal timolol patches (5% timolol, 0.2 mg/cm 2 ) found plasma concentration levels to be below the detection limit after application for 48 h 7 . Consistent with the latter, in our study and in the other reported cases, timolol has to date not produced any systemic adverse reactions when used to treat IHs in the available formulations of 0.1% and 0.5% 2–4 . Nevertheless, the available safety data are still insufficient, and dermatologists should be alert for the known side‐effects of beta‐blockers and thus monitor infants accordingly.…”

Oral Propranolol in the Management of Periocular Capillary Hemangiomas

“…31 Overall, however, the drug seems to be very safe with no serious adverse effects reported when used for this condition. 32 The authors also reported reduction in the average astigmatism from 2.5 to 1.0 D in their patients. Ni and colleagues treated 7 patients with superficial periocular hemangiomas; none of the patients underwent any previous treatment and all were treated using 0.5% solution of timolol maleate.…”

“…' The Role of Topical b Blockers Topical b blockers have been suggested as a safe and effective treatment for superficial hemangiomas with reduced systemic side effects. 32 This experience has been duplicated in other reports that have showed regression or arrested growth in lesions using timolol gel. The solution was spread over the lesion 2 times a day and the authors found a reduction in the hemangiomas by 55% to 95% over a period of 1 to 6 months.…”

Treatment of superficial infantile hemangiomas with timolol: Evaluation of short-term efficacy and safety in infants

“…As expected, no systemic adverse reactions were observed during the treatment period of the study. Furthermore, no adverse effects have been reported in previous studies (2,7,8), with the exception of mild pruritus over the lesion following four weeks of treatment in a case where timolol application was used to treat an 18-month-old female with ulcerated hemangiomas associated with PHACE syndrome (5). In the experience of the authors, patients with bronchial asthma have not experienced attacks during treatment, and it is therefore proposed that timolol may be safely considered for use in the treatment of IH with bronchial asthma, sinus bradycardia and second- and third-degree atrioventricular block; however, there is a requirement for these patients to be observed closely during treatment.…”

Topical timolol maleate for treatment of infantile haemangiomas: preliminary results of a prospective study

“…Studies on the pharmacokinetics and beta‐blocking effects of transdermal timolol patches (5% timolol, 0.2 mg/cm 2 ) found plasma concentration levels to be below the detection limit after application for 48 h 7 . Consistent with the latter, in our study and in the other reported cases, timolol has to date not produced any systemic adverse reactions when used to treat IHs in the available formulations of 0.1% and 0.5% 2–4 . Nevertheless, the available safety data are still insufficient, and dermatologists should be alert for the known side‐effects of beta‐blockers and thus monitor infants accordingly.…”

Oral Propranolol in the Management of Periocular Capillary Hemangiomas

“…31 Overall, however, the drug seems to be very safe with no serious adverse effects reported when used for this condition. 32 The authors also reported reduction in the average astigmatism from 2.5 to 1.0 D in their patients. Ni and colleagues treated 7 patients with superficial periocular hemangiomas; none of the patients underwent any previous treatment and all were treated using 0.5% solution of timolol maleate.…”

“…' The Role of Topical b Blockers Topical b blockers have been suggested as a safe and effective treatment for superficial hemangiomas with reduced systemic side effects. 32 This experience has been duplicated in other reports that have showed regression or arrested growth in lesions using timolol gel. The solution was spread over the lesion 2 times a day and the authors found a reduction in the hemangiomas by 55% to 95% over a period of 1 to 6 months.…”

Treatment of superficial infantile hemangiomas with timolol: Evaluation of short-term efficacy and safety in infants

“…As expected, no systemic adverse reactions were observed during the treatment period of the study. Furthermore, no adverse effects have been reported in previous studies (2,7,8), with the exception of mild pruritus over the lesion following four weeks of treatment in a case where timolol application was used to treat an 18-month-old female with ulcerated hemangiomas associated with PHACE syndrome (5). In the experience of the authors, patients with bronchial asthma have not experienced attacks during treatment, and it is therefore proposed that timolol may be safely considered for use in the treatment of IH with bronchial asthma, sinus bradycardia and second- and third-degree atrioventricular block; however, there is a requirement for these patients to be observed closely during treatment.…”